Last update 11 Dec 2024

Trastuzumab Biosimilar (Prestige BioPharma)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Trastuzumab biosimilar (Hanwha Biologics), 曲妥珠单抗生物类似药(Hanwha Biologics), 曲妥珠单抗生物类似药(Prestige BioPharma Ltd.)
+ [4]
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Breast Cancer
EU
19 Sep 2024
HER2 Positive Breast Cancer
IS
19 Sep 2024
HER2 Positive Breast Cancer
LI
19 Sep 2024
HER2 Positive Breast Cancer
NO
19 Sep 2024
HER2 positive Gastroesophageal Junction Adenocarcinoma
EU
19 Sep 2024
HER2 positive Gastroesophageal Junction Adenocarcinoma
IS
19 Sep 2024
HER2 positive Gastroesophageal Junction Adenocarcinoma
LI
19 Sep 2024
HER2 positive Gastroesophageal Junction Adenocarcinoma
NO
19 Sep 2024
HER2 Positive Stomach Adenocarcinoma
EU
19 Sep 2024
HER2 Positive Stomach Adenocarcinoma
IS
19 Sep 2024
HER2 Positive Stomach Adenocarcinoma
LI
19 Sep 2024
HER2 Positive Stomach Adenocarcinoma
NO
19 Sep 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breast
EU
19 Sep 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breast
IS
19 Sep 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breast
LI
19 Sep 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breast
NO
19 Sep 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Stomach CancerNDA/BLA
CA
01 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
502
(iohnjdscri) = During the posttreatment follow-up period, adverse events were reported for 64 (27.4%) and 72 (29.8%) patients in the HD201 and the reference trastuzumab groups, respectively vbuqheiwxo (wkkwqfteur )
Positive
31 Jan 2023
Referent trastuzumab
Phase 3
HER2 Positive Breast Cancer
Neoadjuvant
ERBB2-positive
474
gbmmqdlrdm(uirewkxmur) = mgniokdyga ohrpjctkeg (qlunyjeyrc )
Similar
03 Dec 2022
Trastuzumab 6 mg/kg/8 mg/kg+docetaxel+epirubicin+cyclophosphamide
gbmmqdlrdm(uirewkxmur) = yfnsmypknb ohrpjctkeg (qlunyjeyrc )
Phase 3
HER2 Positive Breast Cancer
Neoadjuvant
ERBB2 Positive
502
pxsfmaheod(vdyoncdtxk) = nuzfopagfm xdmlyjrrmo (cmjwhafczk )
Similar
03 Mar 2022
pxsfmaheod(vdyoncdtxk) = arqoyriubl xdmlyjrrmo (cmjwhafczk )
Phase 1
-
105
zampfcimvp(kbeeqclgpg) = were within 80%-125% for the comparisons of HD201 to EU-Herceptin or US-Herceptin and EU-Herceptin to US-Herceptin cxryspagwa (xnsnazdzmx )
Positive
01 Aug 2021
Herceptin
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free